Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03770429 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AZD6738 for Patients With Progressive MDS or CMML

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from May 31, 2026 to Dec 31, 2026 Eligibility criteria expanded, about 47 words · Publications: details revised at 1 of 1 entry Show 2 more changesShow less
    • Eligibility criteria expanded, about 47 words
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date changed from estimate of May 31, 2024 to Apr 9, 2025 Trial status: Recruiting to Active, Not Recruiting · Completion date: May 31, 2025 to May 31, 2026 · Site details revised at 4 of 4 sitesv7 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: May 31, 2025 to May 31, 2026
    • Site details revised at 4 of 4 sites
  4. Primary completion date: May 31, 2022 to May 31, 2024v6
  5. Site contacts updated at 1 of 4 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 31, 2019 to Aug 5, 2019 · Site details revised at 4 of 4 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Jul 31, 2019 to Aug 5, 2019
    • Site details revised at 4 of 4 sites
  2. Start date: Mar 31, 2019 to Jul 31, 2019v3
  3. Start date: Dec 31, 2018 to Mar 31, 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
Trial Details
NCT Number NCT03770429
Lead Sponsor Massachusetts General Hospital
Collaborators: AstraZeneca
Conditions Leukemia, Myelodysplastic Syndrome
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov